DeCure's autonomous Psychiatry AI scientist is researching a drug-repurposing hypothesis for schizoid personality disorder — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleSchizoid personality disorder maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for schizoid personality disorder is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
What the evidence adds up to
A 2018 study of 204 Korean probands with schizophrenia and their families (543 family members total) found that seven of ten MMPI personality dimensions were significantly heritable. The three groups—controls, unaffected first-degree relatives, and cases—differed significantly in the expected order of average scores for all heritable dimensions. The authors concluded that aberrations in several personality dimensions could form part of the complexity of schizophrenic syndrome through genetic–environment interactions, but noted limitations in family recruitment and phenotyping.
A 2023 systematic review of case reports and case series on schizoid personality disorder described the condition as characterised by lack of interest in social activities, difficulty expressing emotions, and a preference for being alone. The review stated that professionals believe the disorder is likely caused by genetic, social, and environmental factors. It did not report any quantitative outcomes, response rates, or survival data.
A 2000 review of the biological basis of schizotypal personality disorder noted that schizotypal patients share social isolation, cognitive impairment, imaging and biochemical evidence of brain dysfunction, and genetic similarities with schizophrenic patients, but do not become chronically psychotic. The authors argued that studying these patients could clarify genetic and biological factors in the schizophrenia spectrum and help identify protective factors against florid psychosis.
No drug treatment is mentioned in any of these abstracts. What is missing is any randomised controlled trial of a pharmacological intervention for schizoid personality disorder, any validated biomarker to stratify patients, and any funding for such a trial.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Psychiatry Investigation · 2018 · 2 citations · open access
Heritability and Familiality of MMPI Personality Dimensions in the Korean Families with Schizophrenia
AbstractOBJECTIVE: Categorical syndrome such as schizophrenia could be the complex of many continuous mental structure phenotypes including several personality development/degeneration dimensions. This is the study to search heritability and familiality of MMPI personality dimensions in the Korean schizophrenic LD (Linkage Disequilibrium) families. METHODS: We have recruited 204 probands (with schizophrenia) with their parents and siblings whenever possible. We have used MMPI questionnaires for measuring personality and symptomatic dimensions. Heritabilities of personality dimensions in total 543 family members were estimated using Sequential Oligogenic Linkage Analysis Routines (SOLAR). Personality dimensions in total family members were compared with those in 307 healthy unrelated controls for measuring the familialities using ANOVA analysis. RESULTS: Seven of the 10 MMPI variables were significantly heritable and were included in the subsequent analyses. The three groups (control, unaffected 1st degree relative, case) were found to be significantly different with the expected order of average group scores for all heritable dimensions. CONCLUSION: Our results show that the aberrations in several personality dimensions could form the complexity of schizophrenic syndrome as a result of genetic-environment coactions or interactions in spite of some limitations (recruited family, phenotyping).
Characteristics, treatment and outcomes of Schizoid Personality Disorder: A systematic review of case reports and case series
AbstractSchizoid personality disorder is a mental disease often characterised by a lack of interest in social activities, difficulty expressing emotions and, most importantly, patients prefer being alone and avoid close relations with the rest of the people. Patients with Schizoid personality disorder usually seem detached, solitary and indifferent, leading to difficulties at work and interpersonal correlation. Professionals alleged that this mental health problem is most likely to be caused by several factors, such as genetic, social and environmental aspects. In this paper, studies and cases analysing and comparing the characteristics, treatment and outcome of patients diagnosed with schizoid personality disorder, were reviewed
Irish Journal of Psychological Medicine · 2000 · 0 citations
The biological basis of schizotypal personality disorder
AbstractAbstract Schizotypal personality disorder is the DSM equivalent of the ICD category schizotypal disorder. It may be seen as part of the schizophrenia spectrum of disorders. Patients with schizotypal personality disorder (SPD) share many features with schizophrenic patients. These include symptoms of social isolation and cognitive impairment. They also share imaging and biochemical evidence of brain dysfunction, and genetic similarities. SPD patients, however, for some reason do not become chronically psychotic. The study of schizotypal patients is of great importance in attempting to clarify the genetic and biological basis of the schizophrenia spectrum. It is also important in helping to delineate the differences between schizophrenic and schizotypal patients, and to distinguish those factors that protect the schizotypal patient from becoming floridly psychotic. In this article we present recent findings regarding the biological basis of schizotypal personality disorder. We illustrate the contribution of these findings to our understanding of risk and protective factors in the schizophrenia spectrum.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
